Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Pediatric NMOSD
NCT05346354Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Alexion Pharmaceuticals. Primary endpoints: Annualized Relapse Rate at 50 weeks and Time to First Adjudicated On-trial Relapse at 50 weeks. Started Jun 2022; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05346354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346354.